Corcept Therapeutics Incorporated (CORT) Financial Ratios

Corcept Therapeutics Incorporated (CORT) has an ST Score of 67.8 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate CORT a Buy, with a price target of $125.33 (+7.6% vs the current price). Our ST Score grades it B (67.8/100). The ST Score is a data-driven signal, not a recommendation.

Valuation D, Profitability A+, Financial Strength A-, Momentum A-, Growth B, Forecast C+, Sentiment A+.

Corcept Therapeutics Incorporated (CORT) earns a valuation grade of D, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Corcept Therapeutics Incorporated (CORT) earns a growth grade of B, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Corcept Therapeutics Incorporated (CORT) earns a profitability grade of A+, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Corcept Therapeutics Incorporated (CORT) earns a financial strength grade of A-, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Corcept Therapeutics Incorporated (CORT) is $125.33 from 26 analysts, which is +7.6% versus the recent price of $116.45.

Corcept Therapeutics Incorporated (CORT) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.